cxd101
Small moleculeexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT01977638)
Timeline
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1C=C(CN2CCC(CC2)C3=CC=C(C=C3)C(=O)NC4=CC=CC=C4N)C(C)=N1- Mol. weight
- 403.52 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- NCATS5TNV87ICD2 ↗
Also known as
- cxd101
- cxd101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05873244 | Phase 2 | Aug 21, 2023 | Chinese University of Hong Kong |
| NCT03873025 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Celleron Therapeutics Ltd., Merck, University of London, University of Oxford |
| NCT03993626 | Phase 1/Phase 2 (Phase 2) | May 22, 2018 | Celleron Therapeutics Ltd., University of Oxford |
| NCT01977638 | Phase 1 | Nov 1, 2013 | Cancer Research UK, National Institute for Health Research, United Kingdom, University of Oxford |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 3 | 1 | 2 | 2013 |
| Celleron Therapeutics Ltd. | For profit | 2 | 1 | 1 | 2018 |
| Cancer Research UK | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Chinese University of Hong Kong | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2019 |
| National Institute for Health Research, United Kingdom | Government | 1 | 0 | 1 | 2013 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2019 |
7 organizations
Page 1 / 1